Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies

Similar to other cancers, myeloid malignancies are thought to subvert the immune system during their development. This subversion occurs via both malignant cell-autonomous and non-autonomous mechanisms and involves manipulation of the innate and adaptive immune systems. Multiple strategies are being...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sara Small, Yazan Numan, Leonidas C. Platanias
Formato: article
Lenguaje:EN
Publicado: MDPI AG 2021
Materias:
AML
Acceso en línea:https://doaj.org/article/ae3df64a813045f1920fbc5ebf226af4
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:ae3df64a813045f1920fbc5ebf226af4
record_format dspace
spelling oai:doaj.org-article:ae3df64a813045f1920fbc5ebf226af42021-11-25T16:49:49ZInnate Immune Mechanisms and Immunotherapy of Myeloid Malignancies10.3390/biomedicines91116312227-9059https://doaj.org/article/ae3df64a813045f1920fbc5ebf226af42021-11-01T00:00:00Zhttps://www.mdpi.com/2227-9059/9/11/1631https://doaj.org/toc/2227-9059Similar to other cancers, myeloid malignancies are thought to subvert the immune system during their development. This subversion occurs via both malignant cell-autonomous and non-autonomous mechanisms and involves manipulation of the innate and adaptive immune systems. Multiple strategies are being studied to rejuvenate, redirect, or re-enforce the immune system in order to fight off myeloid malignancies. So far, the most successful strategies include interferon treatment and antibody-based therapies, though chimeric antigen receptor (CAR) cells and immune checkpoint inhibitors are also promising therapies. In this review, we discuss the inherent immune mechanisms of defense against myeloid malignancies, currently-approved agents, and agents under investigation. Overall, we evaluate the efficacy and potential of immuno-oncology in the treatment of myeloid malignancies.Sara SmallYazan NumanLeonidas C. PlataniasMDPI AGarticleimmunotherapyAMLinterferonantibodiesmyeloid malignanciesCAR-TBiology (General)QH301-705.5ENBiomedicines, Vol 9, Iss 1631, p 1631 (2021)
institution DOAJ
collection DOAJ
language EN
topic immunotherapy
AML
interferon
antibodies
myeloid malignancies
CAR-T
Biology (General)
QH301-705.5
spellingShingle immunotherapy
AML
interferon
antibodies
myeloid malignancies
CAR-T
Biology (General)
QH301-705.5
Sara Small
Yazan Numan
Leonidas C. Platanias
Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies
description Similar to other cancers, myeloid malignancies are thought to subvert the immune system during their development. This subversion occurs via both malignant cell-autonomous and non-autonomous mechanisms and involves manipulation of the innate and adaptive immune systems. Multiple strategies are being studied to rejuvenate, redirect, or re-enforce the immune system in order to fight off myeloid malignancies. So far, the most successful strategies include interferon treatment and antibody-based therapies, though chimeric antigen receptor (CAR) cells and immune checkpoint inhibitors are also promising therapies. In this review, we discuss the inherent immune mechanisms of defense against myeloid malignancies, currently-approved agents, and agents under investigation. Overall, we evaluate the efficacy and potential of immuno-oncology in the treatment of myeloid malignancies.
format article
author Sara Small
Yazan Numan
Leonidas C. Platanias
author_facet Sara Small
Yazan Numan
Leonidas C. Platanias
author_sort Sara Small
title Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies
title_short Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies
title_full Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies
title_fullStr Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies
title_full_unstemmed Innate Immune Mechanisms and Immunotherapy of Myeloid Malignancies
title_sort innate immune mechanisms and immunotherapy of myeloid malignancies
publisher MDPI AG
publishDate 2021
url https://doaj.org/article/ae3df64a813045f1920fbc5ebf226af4
work_keys_str_mv AT sarasmall innateimmunemechanismsandimmunotherapyofmyeloidmalignancies
AT yazannuman innateimmunemechanismsandimmunotherapyofmyeloidmalignancies
AT leonidascplatanias innateimmunemechanismsandimmunotherapyofmyeloidmalignancies
_version_ 1718412915984302080